Safety and Efficacy Study to Compare Capecitabine + Bevacizumab Versus Capecitabine, Concomitantly With Radiotherapy as Neoadjuvant Treatment for Patients With Localized and Resectable Rectal Cancer (AVAXEL)

Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)

Status and phase

Completed

Phase 2

Conditions

Rectal Cancer

Treatments

Drug: Bevacizumab + Capecitabine + Radiotherapy

Drug: Capecitabine + Radiotherapy

Study type

Interventional

Funder types

Other

Industry

Identifiers

NCT01043484

TTD-08-05

EudraCT: 2009-010192-24

Details and patient eligibility

About

The purpose of the study is to evaluate the efficacy and safety of the combination of capecitabine + bevacizumab concomitantly with radiotherapy versus capecitabine concomitantly with radiotherapy, as neoadjuvant treatment for patients with localized and resectable rectal cancer.

Enrollment

90 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Written informed consent
Age ≥18 years
ECOG ≤ 1
Histologically confirmed carcinoma of the rectum
Localized and resectable rectal cancer
No metastatic disease
Measurable disease
Life expectancy more than 4 months
Non prior treatment for rectal cancer
Adequate haematological function: leu ≥ 4x 109 /l, Hb ≥10 gr/dl, neutropils≥ 1,5 x 109 /l and platelets ≥100 x 109 /l
Adequate renal function: creatinine ≤ 106 umol/l or calculated creatinine clearance > 50 mL/min
Adequate liver function: AST, ALT and alkaline phosphatase ≤2.5 x UL, bilirubin ≤1.5 x UL
Adequate nutritional weight loss <10% of regular weight and albumin ≥ 35 g/l

Exclusion criteria

Unresectable rectal cancer
Past or current history (within the last 5 years prior to treatment start) of other malignancies.
Patients of childbearing potential not willing to use effective means of contraception.
Clinically significant cardiovascular disease
Lack of physical integrity of the upper gastrointestinal tract, malabsorption syndrome or inability to take oral medication.
Patients subjected to organ allografts who require immunosuppressive treatment.
Severe, non-cicatrized osseous fractures, wounds or ulcers.
Indications of hemorrhagic diathesis or coagulopathy.
Severe, uncontrolled intercurrent infections or other severe, uncontrolled concomitant diseases.
History of unexpected severe reactions to treatment with fluoropyrimidines or known deficiency dihydropyrimidine dehydrogenase deficiency (DPD).
Patients subjected to a major surgical procedure, open biopsy or who have had significant traumatic lesions within the 28 days prior to beginning the treatment of the study or in whom it is foreseen that a major surgical procedure will be necessary during the course of the study; fine-needle aspiration within the 7 days prior to beginning the treatment of the study.
Current or recent use (within the 10 days prior to beginning the treatment of the study) of oral or parenteral anticoagulants at complete doses or thrombolytic agents. The use of low doses of warfarin is allowed, with an International Normalized Ratio [INR] of < 1.5.
Daily chronic treatment with high doses of aspirin (> 325 mg/day) or non-steroid anti-inflammatory medications (which inhibit the platelet function at doses used for treating chronic inflammatory diseases).
Patients who have received any drug or agent/procedure under research, i.e., who have participated in another clinical trial during the 4 weeks prior to beginning the treatment with the medications of the study
Any psychological, familiar conditions suggesting that the patient will not be able to complete the study